FOMX FOAMIX PHARMACEUTICALS LTD

Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1

Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1

REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the fourth quarter ended December 31, 2018, on Thursday, February 28, after the markets close. Foamix will host a conference call and webcast at 8:30 a.m. Eastern Time on Friday, March 1.

Conference Call & Webcast 
Friday, March 1st @ 8:30am Eastern Time 
Toll Free:877-407-0784
International:201-689-8560
Conference ID:13687390
Webcast: 
  
Replays, Available through March 15th: 
Toll-Free:844-512-2921
International:412-317-6671
Conference ID:13687390

A replay will also be archived on the Company’s website at promptly after the conference call.

About Foamix

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our leading clinical stage product candidates are FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne and FMX103, our novel minocycline foam for the treatment of rosacea. We continue to pursue research & development of our proprietary, innovative foam technologies for the treatment of various skin conditions. We currently have development and license agreements relating to our technology with various pharmaceutical companies including LEO Pharma A/S and others.

Foamix uses its website () as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Foamix’s website in addition to following its press releases, filings with the Securities & Exchange Commission, public conference calls, and webcasts.

Contact:

Ilan Hadar, CFO

Foamix Pharmaceuticals Ltd.



U.S. Investor Relations

Michael Rice

LifeSci Advisors, LLC

646-597-6979

Media

Elizabeth Tang, PhD

LifeSci Public Relations

646-863-0222

 

EN
14/02/2019

Underlying

FOMXFOAMIX PHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FOAMIX PHARMACEUTICALS LTD

 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th An...

Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cowen 40th Annual Health Care Conference, taking place March 2-4, 2020 in Boston, Massachusetts. Presentat...

February 25, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topi...

Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced results from an integrated efficacy analysis on the two pivotal Phase 3 clinical trials for FMX103 (minocycline, 1.5% foam) currently under review by the U.S. Food and D...

February 18, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix and Menlo Announce Shareholder Approval of Proposed Merger

Foamix and Menlo Announce Shareholder Approval of Proposed Merger Transaction on Track to Close in early March 2020 REHOVOT, Israel and BRIDGEWATER, N.J. and REDWOOD CITY, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX ) and Menlo Therapeutics Inc. (Nasdaq: MNLO) today announced that the shareholders of Foamix and stockholders of Menlo voted to approve all shareholder and stockholder proposals necessary to complete the previously announced merger at their respective shareholder / stockholder meetings held earlier today. Pending the expiration of a 30...

February 6, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for ...

Foamix Announces Publication of Phase 3 Studies Evaluating FMX103 for the Treatment of Papulopustular Rosacea in Journal of the American Academy of Dermatology REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the (JAAD).  Studies 11 and 12 were conducted by Foamix to support the New Drug Application (NDA) submission of FMX103 (minocycline, 1.5% foam...

February 6, 2020 1 EN
 PRESS RELEASE
Free
FOMX FOAMIX PHARMACE...

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics

Foamix Announces OrbiMed’s Support of Merger with Menlo Therapeutics REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today that OrbiMed Advisors LLC (“OrbiMed”), a significant shareholder of the Company, intends to vote in favor of the proposed merger with Menlo Therapeutics at the Company’s upcoming extraordinary general meeting of shareholders. OrbiMed expressed its support for the transaction in a issued on January 16, 2020. Perceptive Advisor...

January 17, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch